Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of danicopan added to C5 inhibitor therapy in PNH
jRCT2031230248Active, not recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jul 2023
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of danicopan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Alexion Pharmaceuticals. Primary endpoint: Participants Experiencing Treatment-emergent Adverse Events (TEAEs) And Serious TEAEs. Started Jul 2023; status: active, not recruiting.
02
Drugs
danicopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on jRCT2031230248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230248.